👤 Jawad Basit

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
4
Articles
3
Name variants
Also published as: S Basit, Sulman Basit
articles
Jawad Basit, Mushood Ahmed, Priyansha Singh +7 more · 2025 · Endocrinology, diabetes & metabolism · Wiley · added 2026-04-24
Inclisiran, a small interfering RNA (siRNA), reduces the levels of low-density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK Show more
Inclisiran, a small interfering RNA (siRNA), reduces the levels of low-density lipoproteins (LDL) in the body by preventing the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9). However, there is limited pooled data regarding the efficacy and safety of inclisiran in patients with hypercholesterolemia. PubMed/MEDLINE, Embase and the Cochrane Library were searched by investigators from inception till July 2024 to identify randomised controlled trials (RCTs) that investigated inclisiran in patients with hypercholesterolemia. Weighted mean differences (MDs) for continuous outcomes and risk ratios (RRs) for the dichotomous outcomes were pooled. The analysis was conducted using the random effects model, and a p-value of < 0.05 was considered statistically significant. A total of 8 RCTs reporting data for 5016 patients were included in the pooled analysis. Our pooled analysis demonstrated that inclisiran was associated with a significant decline in the % of LDL-C levels (MD = -50.42, 95% CI: -56.15 to -44.70), % of PCSK9 levels (MD = -78.57, 95% CI: -81.64 to -75.50), % of total cholesterol levels in the body (MD = -31.22, 95% CI: -33.08.15 to -29.37), and apo B levels (MD = -41.47, 95% CI: -44.83 to -38.11) when compared with the control group. The risk of all-cause death, cardiovascular death, major adverse cardiovascular events, myocardial infarction, stroke, and serious adverse events remained comparable (p > 0.05) across the two groups. Inclisiran reduces LDL-C, PCSK9, cholesterol and apo-B levels in the body without increasing the risk of serious adverse events. Show less
📄 PDF DOI: 10.1002/edm2.70039
APOB
Jordy Dekker, Rachel Schot, Kimberly A Aldinger +87 more · 2025 · American journal of human genetics · Elsevier · added 2026-04-24
Jordy Dekker, Rachel Schot, Kimberly A Aldinger, David B Everman, Camerun Washington, Julie R Jones, Jennifer A Sullivan, Rebecca C Spillmann, Vandana Shashi, Antonio Vitobello, Anne-Sophie Denommé-Pichon, Anne-Laure Mosca-Boidron, Laurence Perrin, Stéphane Auvin, Maha S Zaki, Joseph G Gleeson, Naomi Meave, Cassidy Wallace, Sophie Nambot, Julian Delanne, Sarah M Ruggiero, Ingo Helbig, Mark P Fitzgerald, Richard J Leventer, Dorothy K Grange, Emanuela Argilli, Elliott H Sherr, Supraja Prakash, Derek E Neilson, Francesco Nicita, Antonella Sferra, Enrico S Bertini, Chiara Aiello, Knut Brockmann, Alexander B Kuranov, Silke Kaulfuss, Sulman Basit, Majed Alluqmani, Ahmad Almatrafi, Jan M Friedman, Colleen Guimond, Faruq Mohammed, Pooja Sharma, Divya Goel, Thomas Wirth, Mathieu Anheim, Paulina Bahena, Asuman Koparir, Konstantinos Kolokotronis, Barbara Vona, Thomas Haaf, Erdmute Kunstmann, Reza Maroofian, Henrike L Sczakiel, Felix Boschann, Mala Misra-Isrie, Raymond J Louie, Elliot S Stolerman, Pedro A Sanchez-Lara, Sandra Mergler, Renske Oegema, Yuri A Zarate, Ariana Kariminejad, Homa Tajsharghi, Shimriet Zeidler, Anneke J A Kievit, Arjan Bouman, Gerarda Cappuccio, Nicola Brunetti-Pierri, Kyra E Stuurman, Dayna Morel Swols, Mustafa Tekin, Jariya Upadia, Donna M Martin, Daniel Craven, Susan M Hiatt, Laura A van de Pol, Felice D'Arco, Henri Margot, Martina Wilke, Soheil Yousefi, Tahsin Stefan Barakat, Monique M van Veghel-Plandsoen, Eleonora Aronica, Jasper Anink, Stephen L Rogers, Kevin C Slep, Dan Doherty, William B Dobyns, Grazia M S Mancini Show less
Microtubule-actin cross-linking factor 1 (MACF1) is a large protein of the spectraplakin family, which is essential for brain development. MACF1 interacts with microtubules through the growth arrest-s Show more
Microtubule-actin cross-linking factor 1 (MACF1) is a large protein of the spectraplakin family, which is essential for brain development. MACF1 interacts with microtubules through the growth arrest-specific 2 (Gas2)-related (GAR) domain. Heterozygous MACF1 missense variants affecting the zinc-binding residues in this domain result in a distinctive cortical and brain stem malformation. Evidence for other MACF1-associated disorders is still limited. Here, we present a cohort of 45 individuals with heterozygous or bi-allelic MACF1 variants to explore the phenotypic spectrum and assess possible pathogenic relevance. We observe that de novo heterozygous missense variants in the EF-hand domains also result in distinctive brain malformation and provide experimental evidence that variants in the EF-hand/GAR module increase microtubule binding, suggestive of a toxic gain of function. Notably, no phenotype-genotype correlation was possible for the remaining heterozygous variants in other domains. A clinical review of eight families with bi-allelic variants reveals a possible complex neurodevelopmental syndrome of the central and peripheral nervous systems. In these individuals, bi-allelic variants mostly affect the Plakin domain. Furthermore, RNA sequencing and chromatin immunoprecipitation (ChIP) analyses of human fetal brain tissue reveal five MACF1 isoforms with region-specific expression, differing in their exon 1 transcription start sites but splicing to a common exon 2. This differential expression explains the frontal-predominant lissencephaly in an individual with a homozygous stop-gain in exon 1 (MACF1-204: c.70C>T [p.Arg24∗]), as this isoform is preferentially expressed in the frontal cortex. We conclude that MACF1-related disorders are strictly linked to domain function and the level of transcript expression, explaining the observed wide clinical heterogeneity. Show less
no PDF DOI: 10.1016/j.ajhg.2025.08.010
MACF1
Abdullah, Pashmina Wiqar Shah, Shoaib Nawaz +4 more · 2020 · Molecular biology reports · Springer · added 2026-04-24
Dyggve melchior clausen syndrome (DMC, MIM 223800) is a very rare autosomal recessive form of skeletal dysplasia associated with various degrees of mental retardation. It is characterized by a progres Show more
Dyggve melchior clausen syndrome (DMC, MIM 223800) is a very rare autosomal recessive form of skeletal dysplasia associated with various degrees of mental retardation. It is characterized by a progressive spondyloepimetaphyseal dysplasia (SEMD) with disproportionate short stature, generalized platyspondyly and lacy iliac crest. Here, we report characterization of large consanguineous family segregating DMC in autosomal recessive manner. Scanning SNP-based human genome identified a 5.3 Mb homozygous region on chromosome 18q21.1-q21.2. Sanger sequencing of the DYM gene, located in the homozygous region, revealed a novel homozygous nonsense variant [c.59 T > A; p.(Leu20*)] in affected members of the family. Analysis of the mRNA, extracted from hair follicles of an affected individual, suggested non-sense mediated decay (NMD) of the truncated transcript. This is the first nonsense and fourth loss of function variant in the DYM gene, causing DMC, reported in the Pakistani population. This study not only extended spectrum of the mutations in the DYM gene but will also facilitate diagnosis of similar other cases in Pakistani population. Show less
no PDF DOI: 10.1007/s11033-020-05774-z
DYM
S Basit, A Wali, A Aziz +3 more · 2011 · Clinical genetics · Blackwell Publishing · added 2026-04-24
Hypotrichosis is a human hereditary hair loss disorder in which affected individuals show sparse to complete absence of hair on scalp and/or on different body parts. To date, at least eight isolated a Show more
Hypotrichosis is a human hereditary hair loss disorder in which affected individuals show sparse to complete absence of hair on scalp and/or on different body parts. To date, at least eight isolated autosomal recessive and dominant forms of hypotrichosis loci have been mapped on different human chromosomes, and the corresponding genes have been identified. Detailed clinical and molecular studies were undertaken of the hereditary hypotrichosis observed in the two consanguineous families (A and B) presented here. Human genome scan, using >500 highly polymorphic microsatellite markers, identified equal evidence of linkage of the hypotrichosis phenotype on chromosomes 12q21.2-q22 and 16q21-q23.1 in both the families. The novel hypotrichosis locus on chromosome 12q21.2-q22 spans 16.3 cM (17.62 Mb), flanked by markers D12S326 and D12S101. At this locus, maximum multipoint logarithm of the odds ratio (LOD) scores of 3.68 and 3.31 were obtained in families A and B, respectively. The second hypotrichosis locus on chromosome 16q21-q23.1, identified in the two families, spans 5.58 cM (8.28 Mb) and is flanked by markers D16S3031 and D16S512. Maximum multipoint LOD scores of 3.17 and 3.31 were obtained with markers mapped at this locus in families A and B, respectively. DNA sequence analysis of six candidate genes (PLEKHG7, SLC6A15, VEZT, DUSP6, KERA and KITLG), located in the linkage interval on chromosome 12q21.2-q22, failed to detect potential sequence variants in the affected individuals of the two families. However, DNA sequence analysis of CDH3 gene, located on chromosome 16q21-q23.1, detected a single base pair homozygous insertion (c.1024₁₀₂₅insG and p.342insGfsX345) in exon 9 in family A and deletion of four base pair (c.1859₁₈₆₂delCTCT and p.620delSfsX629) in exon 13 in family B. We described for the first time digenic inheritance of an autosomal recessive hypotrichosis phenotype in two unlinked loci on chromosomes 12q21.2-q22 and 16q21-q23.1 in two unrelated consanguineous Pakistani families. Show less
no PDF DOI: 10.1111/j.1399-0004.2010.01455.x
DUSP6